NRx Pharmaceuticals reports potential acquisition and financing agreements

NRx Pharmaceuticals ( NASDAQ: NRXP ) subsidiary, HOPE Therapeutics, Monday reported the signing of a non-binding term sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions). In addition to the currently signed non-binding term sheet, the company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues exceeding $100 million. The company anticipates potential operations in the United States, France, and the United Kingdom.

The non-dilutive acquisition funding announced on Monday is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. NRXP +4.33% premarket to $2.

17. Source: Press Release More on NRx Pharmaceuticals NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript NRx Pharmaceuticals announces up to $16M senior secured debt financing Seeking Alpha’s Quant Rating on NRx Pharmaceuticals Historical earnings data for NRx Pharmaceuticals Financial information for NRx Pharmaceuticals.